ESMO 2023 | Key takeaways from the renal and prostate cancer sessions at ESMO 2023

Joaquim Bellmunt, MD, PhD, Harvard Medical School, Boston, MA, discusses the session held at ESMO 2023 dedicated to discussing advancements in renal cancer, where options for patients receiving first-line treatment were discussed. Dr Bellmunt also elaborates on the Phase III CONTACT-02 (NCT04446117) trial discussed in the session for prostate cancer at ESMO 2023, which evaluated the efficacy of immunotherapy, atezolizumab and cabozantinib in the treatment of patients with prostate cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.